许晓明,夏云龙,夏林莺,郭永珍,刘泉池,韩雪,闫文俊

• 1:中国人民解放军空军军医大学第一附属医院(西京医院)心血管内科
• 2:西安交通大学第二附属医院心血管内科
• 3:西北大学公共管理学院

摘要(Abstract)：

射血分数保留的心力衰竭（HFpEF）是一种高度异质性的系统性疾病，也是全球范围内心力衰竭的主要类型。目前HFpEF的药物治疗选择十分有限，尚无针对HFpEF的特异性药物。新近研究表明非药物治疗策略作为常规药物治疗的辅助手段，能有效地改善HFpEF患者的症状、生活质量及心力衰竭再入院风险。主要技术包括CD34~+干细胞移植、内脏大神经射频消融术、房间隔分流术、心房起搏、心肌收缩力调节、左心室扩张器、压力感受器刺激等。本文对近年来HFpEF相关非药物治疗的最新临床证据进行系统性综述，以期加强对HFpEF的治疗策略的认识。

关键词(KeyWords)： 射血分数保留的心力衰竭;非药物治疗;器械治疗;监测预警

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金面上项目（82370252、82370386）

作者(Author): 许晓明,夏云龙,夏林莺,郭永珍,刘泉池,韩雪,闫文俊

参考文献(References)：

• [1]王华,刘宇佳,杨杰孚.心力衰竭流行病学[J].临床心血管病杂志,2023,39(4):243-247.DOI:10.13201/j.issn.1001-1439.2023.04.001.
• [2]国家心血管病中心,国家心血管病专家委员会心力衰竭专业委员会,中国医师协会心力衰竭专业委员会,等.国家心力衰竭指南2023(精简版)[J].中国循环杂志,2023,38(12):1207-1238.DOI:10.3969/j.issn.1000-3614.2023.12.001.
• [3]Redfield MM,Borlaug BA.Heart failure with preserved ejection fraction:a review[J].JAMA,2023,329(10):827-838.DOI:10.1001/jama.2023.2020.
• [4]Campbell P,Rutten FH,Lee MM,et al.Heart failure with preserved ejection fraction:everything the clinician needs to know[J].Lancet,2024,403(10431):1083-1092.DOI:10.1016/S0140-6736(23)02756-3.
• [5]Borlaug BA,Sharma K,Shah SJ,et al.Heart failure with preserved ejection fraction:JACC scientific statement[J].J Am Coll Cardiol,2023,81(18):1810-1834.DOI:10.1016/j.jacc.2023.01.049.
• [6]Xiang B,Zhang R,Wu X,et al.Optimal pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction:a meta-analysis[J].JAMA Netw Open,2022,5(9):e2231963.DOI:10.1001/jamanetworkopen.2022.31963.
• [7]Kim MN,Park SM.Current status of pharmacologic and nonpharmacologic therapy in heart failure with preserved ejection fraction[J].Heart Fail Clin,2021,17(3):463-482.DOI:10.1016/j.hfc.2021.02.008.
• [8]Yan W,Xia Y,Zhao H,et al.Stem cell-based therapy in cardiac repair after myocardial infarction:promise,challenges,and future directions[J].J Mol Cell Cardiol,2024,188:1-14.DOI:10.1016/j.yjmcc.2023.12.009.
• [9]Domaszk O,Skwarek A,Wojciechowska M.In search of the holy grail:stem cell therapy as a novel treatment of heart failure with preserved ejection fraction[J].Int J Mol Sci,2023,24(5):4903.DOI:10.3390/ijms24054903.
• [10]Vrtovec B,Frljak S,Poglajen G,et al.A pilot clinical trial of cell therapy in heart failure with preserved ejection fraction[J].Eur J Heart Fail,2022,24(8):1441-1449.DOI:10.1002/ejhf.2596.
• [11]Fudim M,Ponikowski PP,Burkhoff D,et al.Splanchnic nerve modulation in heart failure:mechanistic overviev,initial clinical experience,and safety considerations[J].Eur J Heart Fail,2021,23(7):1076-1084.DOI:10.1002/ejhf.2196.
• [12]Baghdadi S,Abbas MH,Albouz F,et al.Systematic review of the role of thoracoscopic splanchnicectomy in palliating the pain of patients with chronic pancreatitis[J].Surg Endosc,2008,22(3):580-588.DOI:10.1007/s00464-007-9730-x.
• [13]Malek F,Gajewski P,Zymliński R,et al.Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction:first-in-human clinical trial[J].Eur J Heart Fail,2021,23(7):1134-1143.DOI:10.1002/ejhf.2209.
• [14]Gajewski P,Fudim M,Kittipibul V,et al.Early hemodynamic changes following surgical ablation of the right greater splanchnicnerve for the treatment of heart failure with preserved ejection fraction[J].J Clin Med,2022,11(4):1063.DOI:10.3390/jcm11041063.
• [15]Fudim M,Zirakashvili T,Shaburishvili N,et al.Transvenous right greater splanchnic nerve ablation in heart failure and preserved ejection fraction[J].JACC Heart Fail,2022,10(10):744-752.DOI:10.1016/j.jchf.2022.05.009.
• [16]Fudim M,Fail PS,Litwin SE,et al.Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ej ection fraction:early results of the REBALANCE-HF trial rollin cohort[J].Eur J Heart Fail,2022,24(8):1410-1414.DOI:10.1002/ejhf.2559.
• [17]中国医师协会心血管内科医师分会结构性心脏病专业委员会,中国医师协会心血管内科医师分会心力衰竭专业委员会,中国医师协会心血管外科医师分会结构性心脏病专业委员会,等.房间隔分流器治疗射血分数保留心力衰竭:中国专家认识和建议[J].中国介入心脏病学杂志,2020,28(12):661-666.DOI:10.3969/j.issn.1004-8812.2020.12.001.
• [18]Nanayakkara S,Kaye DM.Device therapy with interatrial shunt devices for heart failure with preserved ejection fraction[J].Heart Fail Rev,2023,28(2):281-286.DOI:10.1007/s10741-022-10236-8.
• [19]Kaye DM,Hasenfuβ G,Neuzil P,et al.One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction[J].Circ Heart Fail,2016,9(12):e003662.DOI:10.1161/CIRCHEARTFAILURE.116.003662.
• [20]Shah SJ,Feldman T,Ricciardi MJ,et al.One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure(REDUCE LAP-HFⅠ)trial:a randomized clinical trial[J].JAMA Cardiol,2018,3(10):968-977.DOI:10.1001/j amacardio.2018.2936.
• [21]Shah SJ,Borlaug BA,Chung ES,et al.Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction(REDUCE LAP-HF II):a randomised,multicentre,blinded,sham-controlled trial[J].Lancet,2022,399(10330):1130-1140.DOI:10.1016/S0140-6736(22)00016-2.
• [22]Wu Y,Song M,Wu M,et al.Advances in device-based treatment of heart failure with preserved ejection fraction:evidence from clinical trials[J].ESC Heart Fail,2024,11(1):13-27.DOI:10.1002/ehf2.14562.
• [23]Eicher JC,Laurent G,MathéA,et al.Atrial dyssynchrony syndrome:an overlooked phenomenon and a potential cause of"diastolic"heart failure[J].Eur J Heart Fail,2012,14(3):248-258.DOI:10.1093/eurjhf/hfrl69.
• [24]Sanchis L,Vannini L,Gabrielli L,et al.Interatrial dyssynchrony may contribute to heart failure symptoms in patients with preserved ejection fraction[J].Echocardiography,2015,32(11):1655-1661.DOI:10.1111/echo.12927.
• [25]Liu S,Guan Z,Zheng X,et al.Impaired left atrial systolic function and inter-atrial dyssynchrony may contribute to symptoms of heart failure with preserved left ventricular ejection fraction:a comprehensive assessment by echocardiography[J].Int J Cardiol,2018,257:177-181.DOI:10.1016/j.ijcard.2017.12.042.
• [26]Laurent G,Eicher JC,Mathe A,et al.Permanent left atrial pacing therapy may improve symptoms in heart failure patientswith preserved ejection fraction and atrial dyssynchrony:a pilot study prior to a national clinical research programme[J].Eur J Heart Fail,2013,15(1):85-93.DOI:10.1093/eurjhf/hfs150.
• [27]Silverman DN,Rambod M,Lustgarten DL,et al.Heart rateinduced myocardial Ca~(2+)retention and left ventricular volume loss in patients with heart failure with preserved ejection fraction[J].J Am Heart Assoc,2020,9(17):e017215.DOI:10.1161/JAHA.120.017215.
• [28]Infeld M,Wahlberg K,Cicero J,et al.Effect of personalized accelerated pacing on quality of life,physical activity,and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction:the myPACE randomized clinical trial[J].JAMA Cardiol,2023,8(3):213-221.DOI:10.1001/jamacardio.2022.5 320.
• [29]Reddy YNV,Koepp KE,Carter R,et al.Rate-adaptive atrial pacing for heart failure with preserved ejection fraction:the RAPID-HF randomized clinical trial[J].JAMA,2023,329(10):801-809.DOI:10.1001/jama.2023.0675.
• [30]Riccardi M,Sammartino AM,Adamo M,et al.Cardiac contractility modulation:an effective treatment strategy for heart failure beyond reduced left ventricular ejection fraction?[J].Heart Fail Rev,2023,28(5):1141-1149.DOI:10.1007/s10741-023-10315-4.
• [31]Aneeq A,Jan M,Nisar S,et al.Cardiac contractility modulation:a new horizon in the management of heart failure with preserved ejection fraction(HFpEF)[J].Cardiovasc Revasc Med,2024,61:110.DOI:10.1016/j.carrev.2023.11.007.
• [32]Seferovic PM,Ponikowski P,Anker SD,et al.Clinical practice update on heart failure 2019:pharmacotherapy,procedures,devices and patient management.An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology[J].Eur J Heart Fail,2019,21(10):1169-1186.DOI:10.1002/ejhf.1531.
• [33]Sorimachi H,Verbrugge FH,Omote K,et al.Longitudinal evolution of cardiac dysfunction in heart failure and preserved ejection fraction with normal natriuretic peptide levels[J].Circulation,2022,146(6):500-502.DOI:10.1161/CIRCUL ATIONAHA.121:058592.
• [34]Tschope C,Van Linthout S,Spillmann F,et al.Cardiac contractility modulation signals improve exercise intolerance and maladaptive regulation of cardiac key proteins for systolic and diastolic function in HFpEF[J].Int J Cardiol,2016,203:1061-1066.DOI:10.1016/j.ij card.2015.10.208.
• [35]Linde C,Grabowski M,Ponikowski P,et al.Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction:a pilot study(CCM-HFpEF)[J].Eur J Heart Fail,2022,24(12):2275-2284.DOI:10.1002/ejhf.2619.
• [36]Weissmann J,Benoliel J,Yap CH,et al.A numerical study of a left ventricular expander for heart failure with preserved ej ection fraction[J].R Soc Open Sci,2023,10(7):230142.DOI:10.1098/rsos.230142.
• [37]Rosalia L,Ozturk C,Shoar S,et al.Device-based solutions to improve cardiac physiology and hemodynamics in heart failure with preserved ejection fraction[J].JACC Basic Transl Sci,2021,6(9-10):772-795.DOI:10.1016/j.jacbts.2021.06.002.
• [38]Feld Y,Reisner Y,Meyer-Brodnitz G,et al.The CORolla device for energy transfer from systole to diastole:a noveltreatment for heart failure with preserved ejection fraction[J].Heart Fail Rev,2023,28(2):307-314.DOI:10.1007/s10741-021-10104-x.
• [39]Floras JS,Ponikowski P.The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction[J].Eur Heart J,2015,36(30):1974-1982b.DOI:10.1093/eurheartj/ehv0 87.
• [40]Abdin A,Lauder L,Fudim M,et al.Neuromodulation interventions in the management of heart failure[J].Eur J Heart Fail,2024,26(2):502-510.DOI:10.1002/ejhf.3147.
• [41]Duncker D,Bauersachs J.Current and future use of neuromodulation in heart failure[J].Eur Heart J Suppl,2022,24(Suppl E):E28-E34.DOI:10.1093/eurheartjsupp/suac031.
• [42]Abraham WT,Zile MR,Weaver FA,et al.Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction[J].JACC Heart Fail,2015,3(6):487-496.DOI:10.1016/j.jchf.2015.02.006.
• [43]Zile MR,Lindenfeld J,Weaver FA,et al.Baroreflex activation therapy in patients with heart failure with reduced ejection fraction[J].J Am Coll Cardiol,2020,76(1):1-13.DOI:10.1016/j.jacc.2020.05.015.
• [44]Bisognano JD,Kaufman CL,Bach DS,et al.Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension:results from European and United States trials of the Rheos system[J].J Am Coll Cardiol,2011,57(17):1787-1788.DOI:10.1016/j.jacc.2010.11.048.
• [45]Clemmer JS,Pruett WA.Modeling the physiological roles of the heart and kidney in heart failure with preserved ejection fraction during baroreflex activation therapy[J].Am J Physiol Heart Circ Physiol,2022,323(3):H597-H607.DOI:10.1152/ajpheart.00329.2022.
• [46]Schwartz PJ,De Ferrari GM,Sanzo A,et al.Long term vagal stimulation in patients with advanced heart failure:first experience in man[J].Eur J Heart Fail,2008,10(9):884-891.DOI:10.1016/j.ej heart.2008.07.016.
• [47]De Ferrari GM,Stolen C,Tuinenburg AE,et al.Long-term vagal stimulation for heart failure:eighteen month results from the neural cardiac therapy for heart failure(NECTAR-HF)trial[J].Int J Cardiol,2017,244:229-234.DOI:10.1016/j.ijcard.2017.06.036.
• [48]Gold MR,Van Veldhuisen D J,Hauptman PJ,et al.Vagus nerve stimulation for the treatment of heart failure:the INOVATEHF trial[J].J Am Coll Cardiol,2016,68(2):149-158.DOI:10.1016/j.j acc.2016.03.525.
• [49]Premchand RK,Sharma K,Mittal S,et al.Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure:results of the ANTHEMHF trial[J].J Card Fail,2014,20(11):808-816.DOI:10.1016/j.cardfail.2014.08.009.
• [50]Kumar HU,Nearing BD,Mittal S,et al.Autonomic regulation therapy in chronic heart failure with preserved/mildly reduced ejection fraction:ANTHEM-HFpEF study results[J].Int J Cardiol,2023,381:37-44.DOI:10.1016/j.ijcard.2023.03.030.
• [51]Tran N,Asad Z,Elkholey K,et al.Autonomic neuromodulation acutely ameliorates left ventricular strain in humans[J].J Cardiovasc Transl Res,2019,12(3):221-230.DOI:10.1007/s12265-018-9853-6.
• [52]Stavrakis S,Elkholey K,Morris L,et al.Neuromodulationof inflammation to treat heart failure with preserved ejection fraction:a pilot randomized clinical trial[J].J Am Heart Assoc,2022,11(3):e023582.DOI:10.1161/JAHA.121.023582.
• [53]Rey-Garcia J.Townsend RR.Renal denervation:a review[J].Am J Kidney Dis,2022,80(4):527-535.DOI:10.1053/j.ajkd.2022.03.015.
• [54]Barbato E,Azizi M,Schmieder RE,et al.Renal denervation in the management of hypertension in adults.A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J].Eur Heart J,2023,44(15):1313-1330.DOI:10.10 9 3/eurheartj/ehad054.
• [55]Weber MA,Mahfoud F,Schmieder RE,et al.Renal denervation for treating hypertension:current scientific and clinical evidence[J].JACC Cardiovasc Interv,2019,12(12):1095-1105.DOI:10.1016/j.jcin.2019.02.050.
• [56]Lohmeier TE,Hall JE.Device-based neuromodulation for resistant hypertension therapy[J].Circ Res,2019,124(7):1071-1093.DOI:10.1161/CIRCRESAHA.118.313221.
• [57]Brandt MC,Mahfoud F,Reda S,et al.Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension[J].J Am Coll Cardiol,2012,59(10):901-909.DOI:10.1016/j.jacc.2011.11.034.
• [58]Patel HC,Rosen SD,Hayward C,et al.Renal denervation in heart failure with preserved ejection fraction(RDT-PEF):a randomized controlled trial[J].Eur J Heart Fail,2016,18(6):703-712.DOI:10.1002/ejhf.502.
• [59]McDonagh TA,Metra M,Adamo M,et al.2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)With the special contribution of the Heart Failure Association(HFA)of the ESC[J].Eur J Heart Fail,2024,26(1):5-17.DOI:10.1002/ejhf.3024.
• [60]Kittleson MM,Panjrath GS,Amancherla K,et al.2023 ACC Expert Consensus decision pathway on management of heart failure with preserved ejection fraction:a report of the American College of Cardiology Solution Set Oversight Committee[J].J Am Coll Cardiol,2023,81(18):1835-1878.DOI:10.1016/j.jacc.2023.03.393.
• [61]射血分数保留的心力衰竭诊断与治疗中国专家共识制定工作组.射血分数保留的心力衰竭诊断与治疗中国专家共识2023[J].中国循环杂志,2023,38(4):375-393.DOI:10.3969/j.issn.1000-3614.2023.04.001.
• [62]中国医院协会心脏康复管理专业委员会,苏州工业园区心血管健康研究院.心脏康复分级诊疗中国专家共识[J].中国介入心脏病学杂志,2022,30(8):561-572.DOI:10.3969/j.issn.1004-8812.2022.08.001.
• [63]Zhuang C,Luo X,Wang Q,et al.The effect of exercise training and physiotherapy on diastolic function,exercise capacity and quality of life in patients with heart failure with preserved ejection fraction:a systematic review and metaanalysis[J].Kardiol Pol,2021,79(10):1107-1115.DOI:10.33963/KP.a2021.0101.
• [64]Bohmke NJ,Billingsley HE,Kirkman DL,et al.Nonpharmacological strategies in heart failure with preserved ejection fraction[J].Cardiol Clin,2022,40(4):491-506.DOI:10.1016/j.ccl.2022.06.003.
• [65]Zile MR,Bennett TD,St John Sutton M,et al.Transition from chronic compensated to acute decompensated heart failure:pathophysiological insights obtained from continuous monitoring of intracardiac pressures[J].Circulation,2008,118(14):1433-1441.DOI:10.1161/CIRCULATION AHA.108.783910.
• [66]Brugts JJ,Radhoe SP,Aydin D,et al.Clinical update of the latest evidence for cardiomems pulmonary artery pressure monitoring in patients with chronic heart failure:a promising system for remote heart failure care[J].Sensors(Basel),2021,21(7):2335.DOI:10.3390/s21072335.
• [67]Abraham WT,Adamson PB,Bourge RC,et al.Wireless pulmonary artery haemodynamic monitoring in chronic heart failure:a randomised controlled trial[J].Lancet,2011,377(9766):658-666.DOI:10.1016/S0140-6736(11)60101-3.
• [68]Adamson PB,Abraham WT,Bourge RC,et al.Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction[J].Circ Heart Fail,2014,7(6):935-944.DOI:10.1161/CIRCHEARTFAILURE.113.001229.
• [69]Shavelle DM,Desai AS,Abraham WT,et al.Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure:oneyear outcomes from the cardiomems post-approval study[J].Circ Heart Fail,2020,13(8):e006863.DOI:10.1161/CIRCHEARTFAILURE.119.006863.
• [70]Latib A,Hashim Mustehsan M,Abraham WT,et al.Transcatheter interventions for heart failure[J].EuroIntervention,2023,18(14):1135-1149.DOI:10.4244/EIJ-D-22-00070.
• [71]Lindenfeld J,Zile MR,Desai AS,et al.Haemodynamic-guided management of heart failure(GUIDE-HF):a randomised controlled trial[J].Lancet,2021,398(10304):991-1001.DOI:10.1016/S0140-6736(21)01754-2.
• [72]Brugts JJ,Radhoe SP,Clephas PRD,et al.Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure(MONITOR-HF):a randomised clinical trial[J].Lancet,2023,401(10394):2113-2123.DOI:10.1016/S0140-6736(23)00923-6.
• [73]Mullens W,Sharif F,Dupont M,et al.Digital health care solution for proactive heart failure management with the Cordella Heart Failure System:results of the SIRONA first-in-human study[J].Eur J Heart Fail,2020,22(10):1912-1919.DOI:10.1002/ejhf.1870.
• [74]Sharif F,Rosenkranz S,Bartunek J,et al.Safety and efficacy of a wireless pulmonary artery pressure sensor:primary endpoint results of the SIRONA 2 clinical trial[J].ESC Heart Fail,2022,9(5):2862-2872.DOI:10.1002/ehf2.14006.
• [75]D'Amario D,Meerkin D,Restivo A,et al.Safety,usability,and performance of a wireless left atrial pressure monitoring system in patients with heart failure:the VECTORHF trial[J].Eur J Heart Fail,2023,25(6):902-911.DOI:10.1002/ejhf.2869.
• [76]Restivo A,D'Amario D,Paglianiti DA,et al.A 3-year single center experience with left atrial pressure remote monitoring:the long and winding road[J].Front Cardiovasc Med,2022,9:899656.DOI:10.3389/fcvm.2022.899656.